BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 31290003)

  • 1. Relative Efficacy of Systemic Treatments for Patients with Advanced Hepatocellular Carcinoma According to Viral Status: A Systematic Review and Network Meta-Analysis.
    Park J; Cho J; Lim JH; Lee MH; Kim J
    Target Oncol; 2019 Aug; 14(4):395-403. PubMed ID: 31290003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-line targ veted therapies of advanced hepatocellular carcinoma: A Bayesian network analysis of randomized controlled trials.
    Ding W; Tan Y; Qian Y; Xue W; Wang Y; Jiang P; Xu X
    PLoS One; 2020; 15(3):e0229492. PubMed ID: 32134981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selection of first-line systemic therapies for advanced hepatocellular carcinoma: A network meta-analysis of randomized controlled trials.
    Han Y; Zhi WH; Xu F; Zhang CB; Huang XQ; Luo JF
    World J Gastroenterol; 2021 May; 27(19):2415-2433. PubMed ID: 34040331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Second-line treatments for Advanced Hepatocellular Carcinoma: A Systematic Review and Bayesian Network Meta-analysis.
    Solimando AG; Susca N; Argentiero A; Brunetti O; Leone P; De Re V; Fasano R; Krebs M; Petracci E; Azzali I; Nanni O; Silvestris N; Vacca A; Racanelli V
    Clin Exp Med; 2022 Feb; 22(1):65-74. PubMed ID: 34146196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Second-line Treatments of Advanced Hepatocellular Carcinoma: Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
    Bakouny Z; Assi T; El Rassy E; Nasr F
    J Clin Gastroenterol; 2019 Apr; 53(4):251-261. PubMed ID: 30575632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment efficacy differences of sorafenib for advanced hepatocellular carcinoma: a meta-analysis of randomized clinical trials.
    Shao YY; Shau WY; Chan SY; Lu LC; Hsu CH; Cheng AL
    Oncology; 2015; 88(6):345-52. PubMed ID: 25572912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathologic characteristics andoutcomes of hepatocellular carcinoma associated with chronic hepatitis B versus hepatitis C infection.
    Aljumah AA; Kuriry H; Faisal N; Alghamdi H
    Ann Saudi Med; 2018; 38(5):358-365. PubMed ID: 30284991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.
    Bruix J; Raoul JL; Sherman M; Mazzaferro V; Bolondi L; Craxi A; Galle PR; Santoro A; Beaugrand M; Sangiovanni A; Porta C; Gerken G; Marrero JA; Nadel A; Shan M; Moscovici M; Voliotis D; Llovet JM
    J Hepatol; 2012 Oct; 57(4):821-9. PubMed ID: 22727733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A systematic review and network meta-analysis of second-line therapy in hepatocellular carcinoma.
    Delos Santos S; Udayakumar S; Nguyen A; Ko YJ; Berry S; Doherty M; Chan KKW
    Curr Oncol; 2020 Dec; 27(6):300-306. PubMed ID: 33380861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postoperative Outcomes for Patients with Non-B Non-C Hepatocellular Carcinoma: A Subgroup Analysis of Patients with a History of Hepatitis B Infection.
    Omichi K; Shindoh J; Yamamoto S; Matsuyama Y; Akamatsu N; Arita J; Kaneko J; Sakamoto Y; Hasegawa K; Kokudo N
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1034-40. PubMed ID: 26350363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of viral hepatitis on outcomes after liver resection for hepatocellular carcinoma: results from a north american center.
    Lee JJ; Kim PT; Fischer S; Fung S; Gallinger S; McGilvray I; Moulton CA; Wei AC; Greig PD; Cleary SP
    Ann Surg Oncol; 2014 Aug; 21(8):2708-16. PubMed ID: 24806113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A systematic review of sorafenib in Child-Pugh A patients with unresectable hepatocellular carcinoma.
    Shen A; Tang C; Wang Y; Chen Y; Yan X; Zhang C; Liu R; Wei X; Zhu Y; Zhang H; Wu Z
    J Clin Gastroenterol; 2013; 47(10):871-80. PubMed ID: 24100749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences in surgical outcomes between hepatitis B- and hepatitis C-related hepatocellular carcinoma: a retrospective analysis of a single North American center.
    Franssen B; Alshebeeb K; Tabrizian P; Marti J; Pierobon ES; Lubezky N; Roayaie S; Florman S; Schwartz ME
    Ann Surg; 2014 Oct; 260(4):650-6; discussion 656-8. PubMed ID: 25203882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of surgical outcomes for hepatocellular carcinoma in patients with hepatitis B versus hepatitis C: a western experience.
    Roayaie S; Haim MB; Emre S; Fishbein TM; Sheiner PA; Miller CM; Schwartz ME
    Ann Surg Oncol; 2000 Dec; 7(10):764-70. PubMed ID: 11129425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-Infiltrating Leukocyte Composition and Prognostic Power in Hepatitis B- and Hepatitis C-Related Hepatocellular Carcinomas.
    Hsiao YW; Chiu LT; Chen CH; Shih WL; Lu TP
    Genes (Basel); 2019 Aug; 10(8):. PubMed ID: 31434354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy for hepatocellular carcinoma: current status and future perspectives.
    Ikeda M; Morizane C; Ueno M; Okusaka T; Ishii H; Furuse J
    Jpn J Clin Oncol; 2018 Feb; 48(2):103-114. PubMed ID: 29253194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between the rs2596542 polymorphism in the MICA gene promoter and HBV/HCV infection-induced hepatocellular carcinoma: a meta-analysis.
    Luo X; Wang Y; Shen A; Deng H; Ye M
    BMC Med Genet; 2019 Aug; 20(1):142. PubMed ID: 31419949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular targeted therapy and immunotherapy in advanced hepatocellular carcinoma: a systematic review and Bayesian network meta-analysis based on randomized controlled trials.
    Zhang YL; Cui XJ; Xing H; Ning HF; Dong P; Wang GZ
    Ann Med; 2023; 55(2):2242384. PubMed ID: 37557186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Which is the best combination of TACE and Sorafenib for advanced hepatocellular carcinoma treatment? A systematic review and network meta-analysis.
    Feng F; Jiang Q; Jia H; Sun H; Chai Y; Li X; Rong G; Zhang Y; Li Z
    Pharmacol Res; 2018 Sep; 135():89-101. PubMed ID: 29959032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic Treatment of Patients with Advanced, Unresectable Hepatocellular Carcinoma: Emergence of Therapies.
    Sun W; Cabrera R
    J Gastrointest Cancer; 2018 Jun; 49(2):107-115. PubMed ID: 29453759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.